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Abstract
Background: Hypertension guidelines recommend ambulatory blood pressure (ABP), central aortic pressure (CAP), and pulse
wave velocity (PWV) as parameters for estimating blood pressure (BP) control and vascular impairment. Recent advances in
technology have enabled devices to combine non-invasive estimation of these parameters over the 24-hour ABP monitoring.
However, currently there is limited evidence on the usefulness of such an approach for routine hypertension management.
Objective: We recently launched an investigator-initiated, international, multicenter, observational, prospective study, the
Vascular health Assessment Of The Hypertensive patients (VASOTENS) Registry, aimed at (1) evaluating non-invasive 24-hour
ABP and arterial stiffness estimates (through 24-hour pulse wave analysis, PWA) in hypertensive subjects undergoing ambulatory
blood pressure monitoring (ABPM) for clinical reasons; (2) assessing the changes in estimates following treatment; (3) weighing
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the impact of 24-hour PWA on target organ damage and cardiovascular prognosis; (4) assessing the relationship between arterial
stiffness, BP absolute mean level and variability, and prognosis; and (5) validating the use of a 24-hour PWA electronic health
(e-health) solution for hypertension screening.
Methods: Approximately 2000 subjects, referred to 20 hypertension clinics for routine diagnostic evaluation and follow-up of
hypertension of any severity or stage, will be recruited. Data collection will include ABPM, performed with a device allowing
simultaneous non-invasive assessment of 24-hour CAP and arterial stiffness (BPLab), and clinical data (including cardiovascular
outcomes). As recommended by current guidelines, each patient will be followed-up with visits occurring at regular intervals
(ideally every 6 months, and not less than once a year depending on disease severity). A Web-based telemedicine platform
(THOLOMEUS) will be used for data collection. The use of the telemedicine system will allow standardized and centralized data
collection, data validation by experts and counseling to remote centers, setup and maintenance of the Registry, and prompt data
analysis.
Results: First follow-up results are expected to be available in the next 2 years.
Conclusions: The results of the VASOTENS Registry will help define the normalcy thresholds for current and future indices
derived from 24-hour PWA, according to outcome data, and will also provide supporting evidence for the inclusion of this type
of evaluation in hypertension management.
Trial registration: Clinicaltrials.gov NCT02577835; https://clinicaltrials.gov/ct2/show/NCT02577835 (Archived by WebCite
at http://www.Webcitation.org/6hzZBKY2Q)
(JMIR Res Protoc 2016;5(2):e137)   doi:10.2196/resprot.5619
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Introduction
Literature Review
Central aortic pressure (CAP) and pulse wave velocity (PWV)
are independent predictors for the development of cardiovascular
(CV) diseases [1-3]. Due to the large amount of epidemiological
evidence for its predictive value for CV events, carotid-femoral
PWV is currently highly indicated and useful for stratification
of total CV risk, and considered the “gold standard”
measurement of arterial stiffness [1,4,5]. Pulse-wave analysis
(PWA), including evaluation of CAP, and Augmentation Index
(AIx), may also provide additional information concerning wave
reflections and may be useful for risk stratification and
evaluation of the effectiveness of treatment, but more evidence
is needed before recommending the routine clinical use of these
vascular indices [1,5].
The most widely adopted methods for evaluating pulse
waveforms are those based on applanation tonometry and
transfer functions [1,6,7]. Notwithstanding the consistent
evidence for superior and independent prognostic value, with
respect to conventional office BP of either indices of central
hemodynamics and stiffness assessed in controlled office
condition at rest [2,3,8,9], currently there are no studies that
evaluated the long-term predictive ability for CV events of
vascular indices (ie, PWV, AIx, and CAP), measured in dynamic
conditions over the 24-hours by ambulatory blood pressure
monitoring (ABPM). However, some incomplete evidence is
available from cross-sectional studies. For example, in 629
patients with diabetes, 24-hour aortic systolic blood pressure
(SBP) was higher than in the 86 control patients, and increased
with diabetic complications, being more strongly associated to
complications than peripheral 24-hour SBP [10]. In the SAFAR
Study [11,12], both 24-hour aortic and brachial SBP were
superior to conventional office BP measurements in predicting
BP-related cardiac damage (left ventricular hypertrophy and
left ventricular diastolic dysfunction) in 230 subjects (75%
having arterial hypertension). In the same study, 24-hour
ambulatory central SBP was also more closely associated with
left ventricular hypertrophy than 24-hour ambulatory brachial
SBP. With respect to arterial stiffness, Aissopou et al [13] found
that ambulatory aortic PWV, estimated by an
operator-independent method, provided additional information
to carotid-femoral PWV regarding the association of arterial
stiffness with the retinal vessel calibers. Elsurer and Afsar [14]
found that in 339 hypertensive patients with chronic kidney
disease, serum uric acid was significantly correlated with both
24-hour PWV and AIx. However, serum uric acid was
independently associated with AIx only. Maloberti and
colleagues [15] studied 19 children with Williams-Beuren
syndrome, a genetic disorder involving the elastin gene and
adversely affecting arterial function and found that sick children
showed higher heart rate and AIx values at night than
age-matched controls, suggesting an abnormal sympathetic
cardiovascular control and an increase in small arteries
resistance. The limited evidence from the literature is completed
by two longitudinal studies. The Ambulatory Central Aortic
Pressure (AmCAP) study described a significant CAP lowering
effect on both day-time and night-time with a 12-week treatment
based on either aliskiren (300 mg) or telmisartan (80 mg)
administered once-daily [16]. Interestingly, this study also
showed relatively higher values of nocturnal aortic than brachial
BP. Karpetas et al [17] and Koutroumbas et al [18] showed a
gradual interdialytic increase in ambulatory CAP and AIx, and
to less extent in PWV, in 153 patients with end stage renal
disease treated with dialysis.
There is previous evidence that non-invasive assessment of
24-hour arterial stiffness and central hemodynamics in daily
life conditions measured by the device used in this study (BPLab
device, BPLab GmbH, Schwalbach am Taunus, Hessen,
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Germany) may help in assessing the arterial function impairment
in hypertensive patients. We recently showed larger 24-hour
CAP and peripheral AIx values in 661 patients with hypertension
compared to 142 normotensive controls [19]. In a subgroup of
137 patients with hypertension, a significantly positive
correlation was found between 24-hour PWV and left ventricular
mass index (LVMI) [20]. In another study, Kuznetsova et al
[21] provided age- and gender-specific reference diagnostic
values for 24-hour PWV, AIx, and CAP in 467 normotensive
volunteers. Minyukhina and colleagues [22] observed a
reduction in 24-hour PWV one week after kidney transplantation
in 41 patients with end-stage renal disease, with a return to
pre-transplant values after 20 weeks. Finally, in another study
the combination of hypertension and chronic obstructive
pulmonary disease was associated with an increased ambulatory
peripheral and central aortic pressure, while this was not the
case for isolated essential hypertensive subjects and
normotensive controls [23].
Rationale
Recent advances in technology enabled devices to combine
non-invasive estimation of CAP and arterial stiffness in
ambulatory conditions over the 24-hours, based on the
oscillometric method [24-28]. Such techniques are affordable
and may allow a comfortable, accurate, repeated, and prolonged
estimation of arterial stiffness and central hemodynamics over
the 24-hours in daily life conditions by ABPM. Recent studies
seem to indicate reliability and feasibility of ambulatory arterial
stiffness and hemodynamics evaluation based on analysis of
brachial oscillograms [8,29,30]. However, at present, there is
limited evidence on the clinical usefulness of such an approach
and much has to be done to prove its actual benefit in the daily
clinical management of hypertension. In particular, there are
very few data on the long-term prognostic and clinical value of
24-hour ambulatory CAP and arterial stiffness estimation, since
most studies performed so far were not sufficiently long lasting
or had a cross-sectional design [11-23]. At the moment, some
associations with CV complications have been demonstrated
for 24-hour CAP, but not for PWV and AIx. In addition, since
different algorithms are used by the different ambulatory
devices, non-invasive estimation of central hemodynamics and
arterial stiffness appears to be device- and/or
technique-dependent, and thus results obtained with one or the
other device cannot be easily confronted and interpreted.
To provide further insight on the matter, we created a large
database (or registry) of ABPM recordings obtained with the
BPLab monitor, which is able to determine CAP, PWV, and
AIx, over the 24-hours, based on a clinically validated
technology of PWA of oscillometric BP measurements [26-28].
The choice of this device was made not only because of its
proved accuracy and clinical reliability, but also because of its
compatibility with the Web-based telemedicine platform
THOLOMEUS (Biotechmed Ltd., Somma Lombardo, Varese
Italy) [31], which enables easy data collection and
communication within such a large worldwide network of study
centers.
This paper summarizes the study protocol (final version, dated
20/02/2015, available as an online supplement to this paper)
(Multimedia Appendix 1) that has been prepared following the
recommendations contained in the SPIRIT statement [32], the
most appropriate checklist for the publication of protocol papers
of observational, non-randomized, prospective studies in the
initial stage (Multimedia Appendix 2).
Study Objectives
The VASOTENS (Vascular health Assessment Of The
Hypertensive patients) Registry aims at evaluating the clinical
value and the prognostic impact of 24-hour ambulatory
non-invasive estimation of arterial stiffness and central
hemodynamics by PWA in patients with hypertension
undergoing an ABPM for clinical reasons in hypertension
clinics. Specific study objectives include (1) the evaluation of
24-hour PWV, AIx and CAP in hypertensive patients over
consecutive ABPMs performed at regular intervals, as
recommended by current guidelines, for a minimum of 2 years
(main study objective); (2) the evaluation of the changes in BP
and arterial stiffness estimates following treatment initiation or
modification, according to current guidelines; (3) the assessment
of the impact of non-invasive arterial stiffness estimation on
cardiac, vascular and renal damage and patient’s CV prognosis
(fatal and non-fatal events); (4) the definition of the normal
thresholds for PWV, AIx and CAP, in hypertensive patients,
according to outcome data; and (5) the definition of the
relationship between arterial stiffness, BP absolute level and
BP variability, and outcomes.
The outcome-based results provided by the VASOTENS
Registry will help establish a worldwide network of certified
centers performing ambulatory PWA and will help validate and
foster the use of the 24-hour PWA electronic health (e-health)
solution for hypertension screening and follow-up. Ultimately,
the study-based evidence of the clinical relevance of 24-hour
non-invasive central arterial stiffness and hemodynamics
assessment may help favor the inclusion of such evaluations
among the standard procedures made available in hypertension
centers, as well as practical recommendations for improving
hypertension management and control.
Trial Design
The VASOTENS Registry is an international, multicenter,
observational, non-randomized, prospective study.
Methods
Study Setting
A minimum of 20 hypertension centers will be involved
worldwide, each providing at least 100 participants, in order to
allow recruitment of a sufficiently consistent sample size able
to demonstrate the study objectives. A list of participating
centers grouped by countries is shown in Multimedia Appendix
3. Initially, hospitals from Italy and Russia will be enrolled
because of their proximity to the study coordinators. Attempts
will be made to select investigators among active members of
international and national hypertension societies, including
membership in the bodies specifically dedicated to blood
pressure and arterial stiffness measurement. This will ensure
high quality standards of data collection and facilitate the
dissemination of information on the project and its findings.
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Eligibility Criteria
Participants referred to the study centers for routine diagnostic
evaluation of hypertension or established hypertensive patients
will be eligible for inclusion in the study. Individuals fulfilling
eligibility criteria (Textbox 1), whose data are contained in
existing databases collected by the participating centers, and
who are regularly followed-up at the center will have priority
for enrolment.
Textbox 1. Study eligibility criteria.
Criteria
• Inclusion criteria
• Male and female
• Age ≥18 years
• Participants referred to routine diagnostic evaluation for hypertension of any severity or stage, or established hypertensive patients
• Good quality ABPM performed for clinical reasons with a BPLab device
• Availability of individual measurements for ABPM on a bpw file (BPLab format)
• Data directly uploaded on the telemedicine platform of the study
• Availability of basic clinical information (see Textbox 2)
• Availability of a signed informed consent form
• Exclusion criteria
• Age <18 years
• Atrial fibrillation, frequent ectopic beats, second or third degree atrioventricular blocks, or other conditions which might make difficult or
unreliable the automatic BP measurement with the oscillometric technique
• Upper arm circumference <22 cm
• Pregnancy
However, naïve hypertensive participants will also be enrolled,
provided that an ABPM is required for evaluating their potential
hypertension status, according to current recommendations
[5,33]. Once enrolled, participants will be visited every 6 or 12
months at the study centers (dependant on disease severity) for
a minimum follow-up of 2 years, and submitted to the
procedures detailed in the next sections.
Study Procedures
The project will not involve any type of diagnostic evaluation
or pharmacological intervention and the investigators will be
free to manage the patients included in the Registry according
to the requirements of clinical practice and current guidelines
[5]. However, as guidelines recommend, each patient will be
followed-up with visits occurring at regular intervals: ideally
every 6 months, and not less than once a year, for a minimum
follow-up of 2 years. The investigators will also be free to use
the information yielded by the ABPM tests for the clinical
management of their patients. At each study visit, an ABPM by
the BPLab device will be performed and patient’s clinical data,
such as family history, anthropometric data, habits, past and
current diseases, therapies, office BP, and laboratory tests,
including evaluation of target organ damage, will be collected
and entered on the electronic case report form (e-CRF) located
on the study website. A detailed list of the clinical data to be
collected during the study is itemized in Textbox 2.
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Textbox 2. Basic demographic and clinical information to be collected during the study.
Demographic and clinical information
• Age
• Gender
• Height (cm)
• Weight (kg)
• Ethnicity
• Superficial distance between jugulum and symphysis (surrogate of aortic length; cm)
• Waist circumference (cm)
• Smoking status
• Alcohol drinking
• Coffee or tea drinking
• Dyslipidemia (yes/no and indication on treatment)
• Diabetes (yes/no and indication on treatment)
• Diagnosis of hypertension (yes/no and indication on treatment)
• Family history of premature CV disease
• Medical history with particular regard to previous and/or concurrent CV diseases
• Office BP (mmHg) and heart rate (bpm) obtained in the same treatment condition as ABPM
• Electrocardiogram (ECG) indication on left ventricular hypertrophy, Sokolow–Lyon and Cornell index)
• Left ventricular mass index (LVMI, as g/m2) at echocardiogram
• When available, diameter of the aorta (aortic annulus, root and sinotubular junction, in cm) and/or cardiac output (as L/min), assessed by the
echocardiogram
• Intima-media thickness (IMT, mm) at carotid ultrasonography
• When available, ankle-brachial index
• Microalbuminuria (as mg/24h) or albumin-creatinine ratio (mg/g), and serum creatinine (g/dL), with subsequent calculation of estimated glomerular
filtration rate (eGFR) by the Cockroft-Gault equation
• When available, PWV (m/s), Aix (%), and CAP (mmHg) taken during the office visit with a validated device different from the BPLab device
(eg, Sphygmocor or Complior)
Ambulatory Blood Pressure Monitoring
Twenty-four hour ABPM will be performed with the BPLab
device, which has been found to be accurate for estimation of
both BP and vascular indices in properly conducted validation
studies [26,27,34-36]. A description of the technique used to
non-invasively assess central hemodynamics and arterial
stiffness by the BPLab device is detailed in a separate section.
Current guidelines will be followed for proper recording
performance [33,37,38]. In order to reduce patient’s discomfort
and to ensure a reliable minimum number of BP measurements
for the subsequent data analysis (particularly for the evaluation
of BP variability), the device will be programmed to measure
BP at least every 20 minutes during the day (providing a
minimum of 3 readings per hour) and at least 30 minutes during
the night (providing a minimum of 2 readings per hour).
Whenever possible, recordings will start between 8 am and 11
am, in order to standardize data collection and comparisons.
The monitoring cuff will be placed on the non-dominant arm,
the lower edge 2 cm above elbow bend, with the bladder
centered on the upper arm, to ensure uniform compression and
decompression during inflation and deflation. In order to allow
the proper evaluation of PWV, the length of the aorta will be
derived by measuring the distance from the sternal notch
(jugulum) to the upper edge of the pubic bone (symphysis). In
the case of obese patients, this superficial morphological
distance will be adjusted by using the frontal projection in
standing position. Up to 2 BP test readings will be triggered
manually before the device is activated for automatic
measurements in order to test its proper functioning. Two
sequential conventional (office) BP and heart rate readings will
also be taken in the sitting position at the time of ABPM
placement (with the same BPLab device or with a validated
automatic or manual BP measuring device), and recorded on
the e-CRF. Patients will be instructed to keep the arm still and
to avoid any movement during each automatic BP measurement.
Patients will be free to attend to their usual daily activities during
ABPM (avoiding strenuous exercise). They will have to
complete a diary in which daily activities (ie, time of sleeping,
time of meals) will be reported together with the time of
occurrence of unusual events or poor night sleep quality. The
patient will come back to the outpatient clinic on the second
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day of the recording (after at least 24 hours) to remove the
monitor. Shortly after device removal, the recording will be
downloaded to a computer using the telemedicine Web platform
of the project. The investigator will obtain the results from the
Web-based analysis software and verify each recording for
compliance with quality criteria (see below for details). In case
of a bad quality recording the investigator will have to repeat
the recording as soon as possible, preferably within 2 days.
Pulse-Wave Analysis
The oscillometric BPLab device will also allow measurements
of ambulatory arterial stiffness and central hemodynamics by
recording pulsatile pressure changes at the brachial artery level.
Briefly, during BP measurement, the pressure waveforms in the
cuff are recorded during a step-by-step deflation and then
digitalized and stored in the device memory. When data are
uploaded on the Web-based telemedicine platform, the software
processes the signal using proprietary mathematical algorithms.
These are based on a specially developed hemodynamic model
to get the PWV and transfer function that utilizes a modification
in a certain frequency range within the acquired pulse signal to
derive the aortic pressure wave, and thus to assess CAP and
AIx. A detailed description of the methodology may be found
elsewhere [26,28,30]. As aforementioned, the accuracy of the
BPLab device for the assessment of vascular indices has been
validated in studies against a non-invasive gold standard [26,27].
Web-Based Telemedicine Platform
Data contained in existing electronic databases or data of newly
enrolled subjects fulfilling the inclusion criteria will be uploaded
and entered on the study website. These data will include ABPM
measures (peripheral or brachial BP, CAP, and arterial stiffness)
obtained with a BPLab device and clinical data. Data collection
will be ensured by a certified Web-based telemedicine platform
(THOLOMEUS, Biotechmed Ltd., Somma Lombardo, Varese
Italy) available on the Tholomeus website [31]. The choice of
using an e-health tool for study management is based on the
potential of such a solution to allow standardized and centralized
data collection, prompt data validation and analysis, effective
study monitoring and auditing, easy and real-time distribution
of software updates, and bug corrections. It will also help
provide advanced screening options for the patients with
hypertension through a worldwide network of expert centers
connected together. ABPM data will be uploaded on the website
as bpw files (original file format of the standard analysis
software of BPLab device, for centers already using such
software) or by plugging the ABPM device to the computer
through a Universal Serial Bus (USB) cable. ABPM data will
be transmitted to the website and analyzed in real-time with
production of an electronic report (as an Acrobat Reader pdf
file) sent by email to the investigator and simultaneously
published on the user-restricted area of the website. The
Web-based telemedicine platform is complemented by an
e-CRF, which will allow entering main patient’s clinical data
into the study database. Access to the website and e-CRF will
be granted through authentication with username and password
according to local data protection and privacy regulations. A
schematic diagram of the workflow of the Web-based
telemedicine platform is shown in Figure 1.
Figure 1. Workflow of the THOLOMEUS Web-based telemedicine system used in the VASOTENS Registry.
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Ethics
The study will be conducted according to Good Clinical Practice
guidelines and the Declaration of Helsinki [39]. The data
collection will start in each center only after approval or
notification (depending on local laws) of the study protocol and
amendments (if any) by the independent ethics committees of
the centers. All participants meeting inclusion criteria and not
meeting exclusion criteria will be fully informed about the study
design and purposes, and asked to give a written informed
consent if willing to participate. All patient-related information
is subject to medical confidentiality and to the local data
protection acts. Data will be pseudonymized before any
aggregate analysis. This means that main data useful to identify
the patient will be replaced with a unique number and thus the
patient’s identity will not be disclosed to third parties, except
the promoter.
Data Quality Control
Given its observational nature, no formal monitoring of the
study is foreseen for this study. However, electronic data
verification will be done remotely by a data manager who will
get in touch with the investigators and, when needed, will ask
the investigator to correct the erroneous data or complete
missing data on the e-CRF. The investigator will be required
to verify and check that the information provided on the e-CRF
is as precise and accurate as possible. The procedures for data
monitoring and verification will be ensured by the presence of
logical checks and range (defined a priori) for the different
variables and by automatic identification of inconsistencies by
the e-CRF used to manage the database. The controls and related
corrections will be made on the e-CRF directly by the
investigator on the website. Since no standardized or centralized
analysis of laboratory tests will be done, except for ABPM,
particular attention will be dedicated to check the congruency
of data collected through ultrasonography, ECG, and
biochemistry.
Dissemination Activities
An important part of the study-related activities will be aimed
at disseminating the knowledge on the correct use of ambulatory
CAP and arterial stiffness estimation in clinical practice and in
research, and thus at achieving a possibly standardized and
widespread use of this integrated technology. Manuscripts
reporting main study results and documents embedding specific
recommendations on the use of the technique will be developed.
All publications related to the study results will be prepared by
the study coordinators with the support of the scientific
committee and will include any investigator significantly
contributing to the success of the study. A complete list of
investigators will be provided at the end of each manuscript.
The original study protocol (with appendices) can be
downloaded from, and any future study results will be published
on the VASOTENS study website.
Statistical Methods
Primary Outcome Measures
The primary study endpoint will consist of the calculations of
the average 24-hour values of PWV, CAP, and AIx during the
study. The main time points will be the baseline versus the end
of the study, corresponding to 2 years following enrolment, but
averages will be computed for each study visit occurring during
the follow-up.
Secondary Outcome Measures
The endpoints considered secondary study variables and
evaluated according to the same timeline applied to the primary
outcome measures are shown in Textbox 3.
Textbox 3. Secondary outcome measures.
Outcome measures
• Average 24-hour brachial (or peripheral) SBP and DBP
• 24-hour brachial SBP and DBP variability estimated by:
• Unweighted standard deviation: the standard deviation of 24-hour mean value of brachial SBP and DBP [40]
• Weighted standard deviation: the standard deviation of the average of all brachial SBP and DBP values during day-time and night-time,
with weights corresponding to the duration of day-time and night-time [41]
• Average real variability (ARV): the mean of the successive absolute differences between adjacent brachial SBP and DBP values over the
24-hours [42]
• Cardiac damage, defined by the presence of cardiac hypertrophy, as determined by echocardiography (LVMI >115 g/m2 in men and >95 g/m2
in women according to the recommendations of the American Society of Echocardiography) [43,44] or ECG (Sokolow-Lyon index >3.5 mV +
R in aVL >1.1 mV or Cornell voltage duration product >244 mV*ms) [5]
• Vascular damage, defined by the presence of carotid wall thickening or plaque (intima media thickness, IMT >0.9 mm) at ultrasonography and,
if available, by an ankle-brachial index (ABI) <0.9 [5]
• Renal damage, defined by microalbuminuria (30-300 mg/24 h) or albumin–creatinine ratio (30–300 mg/g) (preferentially on morning spot urine)
or reduced estimated glomerular filtration rate (eGFR <60 ml/min/1.73 m2) [5]
• Cardiovascular fatal or non-fatal events: death or hospitalization for congestive heart failure, myocardial infarction, angina, stroke or cerebrovascular
accident, renal failure, or other cardiovascular diseases
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Sample Size
Given the observational nature of the study and the lack of
precedent studies with a similar design and objectives, it is
difficult to define a proper sample size. According to the number
of subjects enrolled and followed-up in previous cross-sectional
or prospective trials [10,11,14-21], and considering the number
of participants usually needed to collect a sufficient number of
clinical outcomes in longitudinal population studies based on
ABPM [45], a minimum number of 2000 participants has been
considered for the present study. Ideally, such a sample size
will be able to provide consistent outcome-based information
on the clinical relevance of 24-hour PWA.
Statistical Analysis
Analysis will be performed on all participants with valid ABPM
recordings at study entry and during the follow-up. Principal
derived ABPM variables and arterial stiffness measures will be
immediately calculated once the data will be uploaded on the
website and their quality verified. Analysis of 24-hour
recordings will be preceded by removal of artifacts according
to previously described editing criteria [37,38]. Valid recordings
will be considered those with (1) an interval between
measurements not exceeding 30 minutes during the whole
24-hours; (2) a recording duration of at least 24-hours; (3) at
least 70% of expected number of readings; and (4) at least 20
valid readings during the day-time and 7 during the nigh-time.
Average brachial and central SBP and DBP, and arterial stiffness
indices (PWV and AIx) will be computed by averaging all the
individual readings over the 24-hours, and separately for the
day-time and night-time subperiods, and for each hour of the
recording. Measures of BP variabilities (unweighted standard
deviation, weighted standard deviation and ARV) will also be
computed based on individual readings. Other ABPM variables
of interest (eg, nocturnal BP fall, morning surge, etc) will be
subsequently defined in the framework of sub-analyses based
on the Registry data and calculated according to procedures
specifically defined.
Basic descriptive statistics will be provided for all variables
with calculations of absolute and relative frequencies for
categorical variables and calculation of average value, standard
deviation, and minimum and maximum for continuous variables.
The relationship between BP and arterial stiffness estimates,
and organ damage and prognosis will be evaluated by
appropriate parametric or non parametric tests, depending on
the type of data distribution (normal or non-normal). The
occurrence of any cardiovascular event during the study will
be evaluated by the Kaplan-Meier method. Time-to-event curves
will be drawn and the survival analysis will be performed
according to the Cox proportional hazard model to analyze
predictors of outcomes. Data management and analysis will be
carried out by SPSS for Windows version 20. A P<0.05 will be
considered as the minimum level of statistical significance.
Results
Enrolment of patients in the first study centers started in October
2015. The first data analysis is expected to be performed by the
end of 2017 or early 2018.
Discussion
The VASOTENS Registry is an international, multicenter,
observational, non-randomized, prospective study devised to
evaluate the clinical impact and usefulness of 24-hour PWA for
hypertension management.
Expected Contributions
With respect to all of the studies briefly reviewed in this paper,
our Registry may offer, for the first time, the possibility to shed
light on the role of 24-hour ambulatory central hemodynamics
and stiffness as predictors of cardiovascular outcomes. The
study results may help determine whether the clinical value of
ABPM might be further increased by incorporating information
on ambulatory CAP and stiffness. The results of the
VASOTENS Registry will help define the normalcy thresholds
for current and future indices derived from 24-hour PWA,
according to outcome data. They will also provide supporting
evidence for the inclusion of such evaluations in
recommendations on hypertension management and its possible
impact on the general population health state. Thanks to this
study, an important lack of knowledge will be worked-out and
the foundation for future studies with a more robust design could
be hopefully laid.
Limitations
The non-randomized uncontrolled nature of the study and the
rather wide selection criteria may increase the risk of obtaining
heterogeneous and poorly powered results. In addition, the fact
that patients will be recruited in hypertension centers may result
in a potential selection bias: the sample being unrepresentative
or not fully representative of the general population of patients
with hypertension. Despite these important limitations, we think
that since the study is carried out in a real-life setting and that
it is a longitudinal long-term outcome-driven study, it represents
an important added value.
Dissemination Strategy
An important component of this study is disseminating the
knowledge on correct use of ambulatory CAP and arterial
stiffness estimation and to help create an e-health network for
a standardized and widespread use of this hypertension screening
tool. In order to achieve this, apart from data collection, several
disseminating activities are required. An exchange of knowledge
between participating centers will be achieved by the
cooperation of investigators in preparing a possibly unified
methodology of ABPM data collection and analysis and by
jointly addressing methodological issues that may arise during
the project. Data collected in the Registry will foster the
performance of studies aimed at optimizing a possible clinical
application of non-invasive ambulatory arterial stiffness
estimation. The study will help provide instructions on
appropriate ambulatory arterial stiffness monitoring
methodology to other physicians, particularly to intermediate
level centers, not necessarily experts in ABPM use and arterial
stiffness determination. A major task of the consortium will be
to provide these participants with accurate information on
correct methodology and interpretation of such data, in order
to support them in case of difficulties and to monitor the
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correctness of the use of the methodology in these centers during
the project. The study findings will favor preparation of specific
recommendations on the use and clinical application of ABPM
integrated with arterial stiffness evaluation. The study will also
ensure cooperation between international and national scientific
societies in the area related to ABPM and arterial stiffness
monitoring. This will facilitate the dissemination of information
on the project and its findings and will also allow an interaction
with writing committees involved in the preparation of
guidelines pertinent to this area
Conclusions
The results of the data collected at baseline and during regular
follow-up of hypertensive patients in the VASOTENS Registry
will help define the normalcy thresholds for current and future
indices derived from 24-hour PWA, according to outcome data.
They will also provide supporting evidence on the clinical
usefulness of such a technological approach, based on
telemedicine, for the screening and follow-up of the vascular
function status of the patients with hypertension.
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